Aura Biosciences to Present at Major Investment Conference
Aura Biosciences, Inc. (NASDAQ: AURA) is making headlines in the biotechnology sector as they gear up for a presentation at the prestigious H.C. Wainwright 27th Annual Global Investment Conference. The event takes place soon, where CEO Elisabet de los Pinos, PhD, will represent the company and share significant updates about their innovative approaches to cancer treatment. This conference is an excellent platform for fostering connections and discussing advancements in the biotechnology field.
Company Overview and Mission
Aura Biosciences is a prominent clinical-stage biotechnology company that focuses on creating precision therapies aimed at treating solid tumors. Their mission includes not only enhancing the efficacy of these treatments but also ensuring they preserve essential organ functions. Their lead candidate, bel-sar (AU-011), is actively undergoing late-stage development for early choroidal melanoma and early-stage development for other ocular oncology indications, as well as bladder cancer. Their commitment to innovation is unparalleled, establishing them as a transformative player in the oncology landscape.
Upcoming Presentation Details
Dr. de los Pinos is set to present on September 10, 2025, at 11:00 a.m. ET during this renowned investment conference. Attendees will have the opportunity to gain insights into Aura's strategic direction, clinical advancements, and the impact of their therapies on patient outcomes. The presentation will also be accessible via a live webcast, ensuring a wide audience of investors and interested parties can stay informed.
Accessing the Presentation
The live webcast of the conference will be hosted on the 'Investors & Media' section on Aura's website. Following the event, a recorded version will be available for 90 days for those who wish to revisit the presentation or access it after the event has concluded. This demonstrates Aura’s dedication to transparency and investor engagement.
About Aura Biosciences' Innovations
Aura focuses on the development of therapies that target primary tumors while preserving healthy tissues, enhancing treatment safety and quality of life for patients. With its innovative product pipeline, the company stands to make significant strides in how solid tumors are treated in clinical settings. The company prides itself on being at the forefront of a competitive market, with a clear focus on oncology and patient care.
Contact and Connect with Aura Biosciences
For additional information about their groundbreaking work and updates, visit aurabiosciences.com. Interested parties can also connect with Aura on X (formerly Twitter) @AuraBiosciences and follow their updates on LinkedIn.
Investor Relations Contact
If you have inquiries or need more information, reach out to:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
Frequently Asked Questions
What is the focus of Aura Biosciences?
Aura Biosciences specializes in developing precision therapies for solid tumors while aiming to preserve organ function.
Who will present at the H.C. Wainwright conference?
CEO Elisabet de los Pinos, PhD will represent Aura Biosciences at the conference.
How can I access the presentation?
The live presentation will be available on Aura's 'Investors & Media' page, with a replay archived for 90 days.
What is the significance of bel-sar (AU-011)?
Bel-sar (AU-011) is Aura’s lead candidate, targeting early-stage choroidal melanoma and other cancer indications, pivotal in their therapy development.
How can I follow updates from Aura Biosciences?
You can visit their website or connect with them on X and LinkedIn for the latest news and updates.
